SCEMBLIX is a kinase inhibitor indicated for the treatment of adult patients with: Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs).

...No evidence of extramedullary leukemic involvement, with the exception of hepatosplenomegaly• Prior treatment with a minimum of one TKI.• Failure or intolerance to the most recent TKI therapy at the time of screening.• Evidence of typical BCR-ABL fusion gene (BCR-ABL1) transcript [e14a2 and/or e13a2] at the time of screening which are amenable to standardized real time quantitative polymerase chain reaction (RQ-PCR) quantification.`...

Asciminib demonstrated promising clinical efficacy with satisfactory tolerance in this cohort of Ph+ leukaemias failing multiple lines of therapy.